美国生物制药公司再生元与生物技术公司阿尔尼拉姆将联合开发用于眼科与中枢神经系统疾病基因干预疗法。再生元已向阿尔尼拉姆投入4亿美元现金并购买4亿美元股票。
Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced a collaboration to discover, develop and commercialize new RNA interference therapeutics focused on ocular and Central Nervous System diseases.
再生元 $Regeneron Pharmaceuticals(REGN)$ 与 Alnylam Pharmaceuticals宣布合作，发现、开发和商业化新的 RNA 干扰疗法，专注于眼科和中枢神经系统疾病。
Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments. The companies plan to advance programs directed to 30 targets and introduce many into clinical development during the initial five-year discovery period, which includes an option to extend.
再生元将领导针对眼科疾病的所有项目的开发和商业化， Alnyam 有权获得潜在的里程碑和专利使用费。这两家公司计划推进针对30个目标的项目，并在最初的五年发现期间将许多项目引入临床开发，其中包括延期选项。
Regeneron has agreed to make a $400 million upfront payment to Alnylam and to purchase $400 million of Alnylam equity at a price per share of $90.00 (4.44 million common shares).
再生元已同意向 Alnyam 支付4亿美元预付款，并以每股90.00美元（444万股普通股）的价格购买4亿美元 Alnyam 股权。
Alnylam is eligible to receive up to an additional $200 million in milestone payments upon achievement of certain criteria during early clinical development for the eye and CNS programs.
在眼睛和中枢神经系统项目的早期临床开发过程中，如果达到某些标准， Alnyam 有资格获得多达2亿美元的里程碑付款。
The collaboration will build on Alnylam's recent preclinical data showing potent delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. The collaboration also includes a select number of RNAi therapeutic programs designed to target genes expressed in the liver, which can influence a wide variety of diseases throughout the body.
此次合作将建立在 Alnyam 近期临床前数据的基础上，该数据显示了 RNAi 疗法的有效应用，以实现目标基因在眼睛和中枢神经系统的沉默。该合作还包括一些选择性的 RNAi 治疗方案，旨在针对肝脏中表达的基因，这可能影响到整个身体的各种疾病。
精彩评论